Testing metformin to reduce inflammation in insulin-resistant breast cancer survivors
Official title: Pilot-Project 1
Funded at University of California Riverside · NIH-10933477 · Data updated 2026-11-12
This study is looking at whether the diabetes medication metformin can help reduce inflammation in women who have survived breast cancer and have insulin resistance, and it’s designed to support participants with training and guidance throughout the process.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Riverside NIH-funded |
| Lab location | 1 site (Riverside, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $49,674 |
| NIH project number | 5U54CA285114-02 |
| Project ID | NIH-10933477 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women who are breast cancer survivors and have been diagnosed with insulin resistance.
✕Less likely to help
Patients who do not have a history of breast cancer or insulin resistance may not benefit from this research.
What this research studies
This research aims to build therapeutic trial capacity at the University of California, Riverside (UCR) by implementing a trial that tests the effectiveness of metformin in reducing inflammation among women who are breast cancer survivors and have insulin resistance. The study will utilize advanced techniques like single-cell transcriptomics and ATAC sequencing to analyze the biological effects of metformin on inflammatory responses. The trial will be conducted in collaboration with the City of Hope Comprehensive Cancer Center, which has extensive experience in running therapeutic trials. Participants will receive hands-on training and support throughout the trial process to ensure rigorous and reproducible results.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic approach to reduce inflammation in breast cancer survivors, potentially improving their overall health and quality of life.
How similar studies have gone: Previous research has shown promising results in using metformin for reducing inflammation in similar patient populations, indicating potential for success in this approach.
Where this research is happening
-
University of California Riverside
Riverside, United States Active
Researchers
- Principal investigator: Davis, Kendrick — University of California Riverside
- Study coordinator: Davis, Kendrick
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.